Home Cardiovascular and metabolic risk in pediatric patients with congenital adrenal hyperplasia due to 21 hydroxylase deficiency
Article
Licensed
Unlicensed Requires Authentication

Cardiovascular and metabolic risk in pediatric patients with congenital adrenal hyperplasia due to 21 hydroxylase deficiency

  • Christiaan F. Mooij , Antonius E. van Herwaarden , Fred C.G.J. Sweep , Nel Roeleveld , Chris L. de Korte , Livia Kapusta and Hedi L. Claahsen-van der Grinten EMAIL logo
Published/Copyright: August 8, 2017
Journal of Pediatric Endocrinology and Metabolism
From the journal Journal of Pediatric Endocrinology and Metabolism Volume 30 Issue 9

Abstract

Background:

The aim of the study was to evaluate the cardiovascular and metabolic risk profile in pediatric patients with congenital adrenal hyperplasia (CAH).

Methods:

A cross-sectional study was performed in 27 CAH patients (8–16 years). Blood samples were taken to evaluate circulating cardiovascular risk (CVR) markers. Insulin resistance (IR) was evaluated by homeostatic model assessment (HOMA)-IR. Blood pressure (BP) was evaluated by office BP measurements and 24-h ambulatory BP measurements (24-h ABPM). Dual energy X-ray absorptiometry (DXA) scans were performed in patients >12 years.

Results:

Body mass index (BMI) standard deviation score (SDS) was elevated (0.67), with seven patients being overweight and four obese. DXA scans showed percentage body fat SDS of 1.59. Office BP levels were higher than reference values. Twenty-four hour ABPM showed systolic hypertension (n=5), while 11 patients had a non-dipping BP profile. HOMA-IR was >75th percentile in 12 patients.

Conclusions:

CAH patients develop an unfavorable CVR profile already in childhood with increased BMI, increased fat mass, elevated BP levels, a non-dipping BP profile and IR compared to population reference values.

Keywords: cardiovascular risk; congenital adrenal hyperplasia; hypertension; insulin resistance; obesity
Corresponding author: Hedi L. Claahsen-van der Grinten, MD, PhD, Division of Pediatric Endocrinology, Department of Pediatrics, Amalia Children’s Hospital, Radboud University Medical Center, (804) PO Box 9101, 6500 HB, Nijmegen, The Netherlands, Phone: +31 24 3614430, Fax: +31 24 3614427

  1. Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.

  2. Research funding: This work was supported by ZonMW (AGIKO Grant to Christiaan F. Mooij) and Stichting Kindercardiologie Nijmegen (research grant to Christiaan F. Mooij).

  3. Employment or leadership: None declared.

  4. Honorarium: None declared.

  5. Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.

References

1. Mooij CF, Kroese JM, Claahsen-van der Grinten HL, Tack CJ, Hermus AR. Unfavourable trends in cardiovascular and metabolic risk in paediatric and adult patients with congenital adrenal hyperplasia? Clin Endocrinol (Oxf) 2010;73:137–46.10.1111/j.1365-2265.2009.03690.xSearch in Google Scholar PubMed

2. Mooij CF, Kroese JM, Sweep FC, Hermus AR, Tack CJ. Adult patients with congenital adrenal hyperplasia have elevated blood pressure but otherwise a normal cardiovascular risk profile. PLoS One 2011;6:e24204.10.1371/journal.pone.0024204Search in Google Scholar PubMed PubMed Central

3. Kroese JM, Mooij CF, van der Graaf M, Hermus AR, Tack CJ. Pioglitazone improves insulin resistance and decreases blood pressure in adult patients with congenital adrenal hyperplasia. Eur J Endocrinol 2009;161:887–94.10.1530/EJE-09-0523Search in Google Scholar PubMed

4. Finkielstain GP, Kim MS, Sinaii N, Nishitani M, Van Ryzin C, et al. Clinical characteristics of a cohort of 244 patients with congenital adrenal hyperplasia. J Clin Endocrinol Metab 2012;97:4429–38.10.1210/jc.2012-2102Search in Google Scholar PubMed PubMed Central

5. Subbarayan A, Dattani MT, Peters CJ, Hindmarsh PC. Cardiovascular risk factors in children and adolescents with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Clin Endocrinol (Oxf) 2014;80:471–7.10.1111/cen.12265Search in Google Scholar PubMed PubMed Central

6. Falhammar H, Filipsson Nystrom H, Wedell A, Thoren M. Cardiovascular risk, metabolic profile, and body composition in adult males with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Eur J Endocrinol 2011;164:285–93.10.1530/EJE-10-0877Search in Google Scholar PubMed

7. Arlt W, Willis DS, Wild SH, Krone N, Doherty EJ, et al. Health status of adults with congenital adrenal hyperplasia: a cohort study of 203 patients. J Clin Endocrinol Metab 2010;95:5110–21.10.1210/jc.2010-0917Search in Google Scholar PubMed PubMed Central

8. Nermoen I, Bronstad I, Fougner KJ, Svartberg J, Oksnes M, et al. Genetic, anthropometric and metabolic features of adult Norwegian patients with 21-hydroxylase deficiency. Eur J Endocrinol 2012;167:507–16.10.1530/EJE-12-0196Search in Google Scholar PubMed

9. Kim MS, Ryabets-Lienhard A, Dao-Tran A, Mittelman SD, Gilsanz V, et al. Increased Abdominal Adiposity in Adolescents and Young Adults With Classical Congenital Adrenal Hyperplasia due to 21-Hydroxylase Deficiency. J Clin Endocrinol Metab 2015;100:E1153–9.10.1210/jc.2014-4033Search in Google Scholar PubMed PubMed Central

10. Sartorato P, Zulian E, Benedini S, Mariniello B, Schiavi F, et al. Cardiovascular risk factors and ultrasound evaluation of intima-media thickness at common carotids, carotid bulbs, and femoral and abdominal aorta arteries in patients with classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Clin Endocrinol Metab 2007;92:1015–8.10.1210/jc.2006-1711Search in Google Scholar PubMed

11. Wasniewska M, Balsamo A, Valenzise M, Manganaro A, Faggioli G, et al. Increased large artery intima media thickness in adolescents with either classical or non-classical congenital adrenal hyperplasia. J Endocrinol Invest 2013;36:12–5.10.1007/BF03346751Search in Google Scholar

12. Charmandari E, Weise M, Bornstein SR, Eisenhofer G, Keil MF, et al. Children with classic congenital adrenal hyperplasia have elevated serum leptin concentrations and insulin resistance: potential clinical implications. J Clin Endocrinol Metab 2002;87:2114–20.10.1210/jcem.87.5.8456Search in Google Scholar PubMed

13. Williams RM, Deeb A, Ong KK, Bich W, Murgatroyd PR, et al. Insulin sensitivity and body composition in children with classical and nonclassical congenital adrenal hyperplasia. Clin Endocrinol (Oxf) 2010;72:155–60.10.1111/j.1365-2265.2009.03587.xSearch in Google Scholar PubMed

14. Moreira RP, Villares SM, Madureira G, Mendonca BB, Bachega TA. Obesity and familial predisposition are significant determining factors of an adverse metabolic profile in young patients with congenital adrenal hyperplasia. Horm Res Pediatr 2013;80:111–8.10.1159/000353762Search in Google Scholar PubMed

15. Volkl TM, Simm D, Beier C, Dorr HG. Obesity among children and adolescents with classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Pediatrics 2006;117:e98–105.10.1542/peds.2005-1005Search in Google Scholar PubMed

16. Cornean RE, Hindmarsh PC, Brook CG. Obesity in 21-hydroxylase deficient patients. Arch Dis Child 1998;78:261–3.10.1136/adc.78.3.261Search in Google Scholar PubMed PubMed Central

17. Amr NH, Ahmed AY, Ibrahim YA. Carotid intima media thickness and other cardiovascular risk factors in children with congenital adrenal hyperplasia. J Endocrinol Invest 2014;37:1001–8.10.1007/s40618-014-0148-8Search in Google Scholar PubMed

18. Akyurek N, Atabek ME, Eklioglu BS, Alp H. Ambulatory blood pressure and subclinical cardiovascular disease in patients with congenital adrenal hyperplasia: a preliminary report. J Clin Res Pediatr Endocrinol 2015;7:13–8.10.4274/jcrpe.1658Search in Google Scholar PubMed PubMed Central

19. Marra AM, Improda N, Capalbo D, Salzano A, Arcopinto M, et al. Cardiovascular abnormalities and impaired exercise performance in adolescents with congenital adrenal hyperplasia. J Clin Endocrinol Metab 2015;100:644–52.10.1210/jc.2014-1805Search in Google Scholar PubMed

20. Bonfig W, Roehl FW, Riedl S, Dorr HG, Bettendorf M, et al. Blood pressure in a large cohort of children and adolescents with classic adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency. Am J Hypertens 2016;29:266–72.10.1093/ajh/hpv087Search in Google Scholar PubMed

21. Maccabee-Ryaboy N, Thomas W, Kyllo J, Lteif A, Petryk A, et al. Hypertension in children with congenital adrenal hyperplasia. Clin Endocrinol (Oxf) 2016;85:528–34.10.1111/cen.13086Search in Google Scholar

22. Grebenschikov N, Geurts-Moespot A, De Witte H, Heuvel J, Leake R, et al. A sensitive and robust assay for urokinase and tissue-type plasminogen activators (uPA and tPA) and their inhibitor type I (PAI-1) in breast tumor cytosols. Int J Biol Markers 1997;12:6–14.10.1177/172460089701200102Search in Google Scholar

23. Grebenschikov N, Sweep F, Geurts A, Andreasen P, De Witte H, et al. ELISA for complexes of urokinase-type and tissue-type plasminogen activators with their type-1 inhibitor (uPA-PAI-1 and tPA-PAI-1). Int J Cancer 1999;81:598–606.10.1002/(SICI)1097-0215(19990517)81:4<598::AID-IJC16>3.0.CO;2-9Search in Google Scholar

24. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412–9.10.1007/BF00280883Search in Google Scholar

25. Shashaj B, Luciano R, Contoli B, Morino GS, Spreghini MR, et al. Reference ranges of HOMA-IR in normal-weight and obese young Caucasians. Acta diabetol 2016;53:251–60.10.1007/s00592-015-0782-4Search in Google Scholar

26. Daniels SR, Greer FR, Committee on Nutrition. Lipid screening and cardiovascular health in childhood. Pediatrics 2008;122:198–208.10.1542/peds.2008-1349Search in Google Scholar

27. Majewska KA, Majewski D, Skowronska B, Stankiewicz W, Fichna P. Serum leptin and adiponectin levels in children with type 1 diabetes mellitus – Relation to body fat mass and disease course. Adv Med Sci 2016;61:117–22.10.1016/j.advms.2015.10.002Search in Google Scholar

28. Fredriks AM, van Buuren S, Fekkes M, Verloove-Vanhorick SP, Wit JM. Are age references for waist circumference, hip circumference and waist-hip ratio in Dutch children useful in clinical practice? Eur J Pediatr 2005;164:216–22.10.1007/s00431-004-1586-7Search in Google Scholar

29. National High Blood Pressure Education Program Working Group on High Blood Pressure in C, Adolescents. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics 2004;114(2 Suppl 4th Report):555–76.10.1542/peds.114.S2.555Search in Google Scholar

30. Wuhl E, Witte K, Soergel M, Mehls O, Schaefer F, et al. Distribution of 24-h ambulatory blood pressure in children: normalized reference values and role of body dimensions. J Hypertens 2002;20:1995–2007.10.1097/00004872-200210000-00019Search in Google Scholar

31. Birkenhager AM, van den Meiracker AH. Causes and consequences of a non-dipping blood pressure profile. Neth J Med 2007;65:127–31.Search in Google Scholar

32. Bohm B, Hartmann K, Buck M, Oberhoffer R. Sex differences of carotid intima-media thickness in healthy children and adolescents. Atherosclerosis 2009;206:458–63.10.1016/j.atherosclerosis.2009.03.016Search in Google Scholar PubMed

33. Sala A, Webber CE, Morrison J, Beaumont LF, Barr RD. Whole-body bone mineral content, lean body mass, and fat mass measured by dual-energy X-ray absorptiometry in a population of normal Canadian children and adolescents. Can Assoc Radiol J 2007;58:46–52.Search in Google Scholar

34. van der Sluis IM, de Ridder MA, Boot AM, Krenning EP, de Muinck Keizer-Schrama SM. Reference data for bone density and body composition measured with dual energy x ray absorptiometry in white children and young adults. Arch Dis Child 2002;87:341–7.10.1136/adc.87.4.341Search in Google Scholar PubMed PubMed Central

35. Aasen G, Fagertun H, Halse J. Body composition analysis by dual X-ray absorptiometry: in vivo and in vitro comparison of three different fan-beam instruments. Scand J Clin Lab Invest 2006;66:659–66.10.1080/00365510600898214Search in Google Scholar PubMed

36. Charmandari E, Chrousos GP. Metabolic syndrome manifestations in classic congenital adrenal hyperplasia: do they predispose to atherosclerotic cardiovascular disease and secondary polycystic ovary syndrome? Ann N Y Acad Sci 2006;1083:37–53.10.1196/annals.1367.005Search in Google Scholar PubMed

37. Sainz N, Barrenetxe J, Moreno-Aliaga MJ, Martinez JA. Leptin resistance and diet-induced obesity: central and peripheral actions of leptin. Metabolism 2015;64:35–46.10.1016/j.metabol.2014.10.015Search in Google Scholar PubMed

38. Wajchenberg BL. Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome. Endocr Rev 2000;21:697–738.10.1210/edrv.21.6.0415Search in Google Scholar PubMed

39. Reinehr T, Kulle A, Wolters B, Lass N, Welzel M, et al. Steroid hormone profiles in prepubertal obese children before and after weight loss. J Clin Endocrinol Metab 2013;98:E1022–30.10.1210/jc.2013-1173Search in Google Scholar PubMed

40. Isguven P, Arslanoglu I, Mesutoglu N, Yildiz M, Erguven M. Bioelectrical impedance analysis of body fatness in childhood congenital adrenal hyperplasia and its metabolic correlates. Eur J Pediatr 2008;167:1263–8.10.1007/s00431-007-0665-ySearch in Google Scholar PubMed

41. Stikkelbroeck NM, Oyen WJ, van der Wilt GJ, Hermus AR, Otten BJ. Normal bone mineral density and lean body mass, but increased fat mass, in young adult patients with congenital adrenal hyperplasia. J Clin Endocrinol Metab 2003;88:1036–42.10.1210/jc.2002-021074Search in Google Scholar PubMed

42. Mnif MF, Kamoun M, Mnif F, Charfi N, Naceur BB, et al. Metabolic profile and cardiovascular risk factors in adult patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Indian J Endocrinol Metab 2012;16:939–46.10.4103/2230-8210.102995Search in Google Scholar PubMed PubMed Central

43. Falhammar H, Filipsson H, Holmdahl G, Janson PO, Nordenskjold A, et al. Metabolic profile and body composition in adult women with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Clin Endocrinol Metab 2007;92:110–6.10.1210/jc.2006-1350Search in Google Scholar PubMed

44. Roche EF, Charmandari E, Dattani MT, Hindmarsh PC. Blood pressure in children and adolescents with congenital adrenal hyperplasia (21-hydroxylase deficiency): a preliminary report. Clin Endocrinol (Oxf) 2003;58:589–96.10.1046/j.1365-2265.2003.01757.xSearch in Google Scholar PubMed

45. Volkl TM, Simm D, Dotsch J, Rascher W, Dorr HG. Altered 24-hour blood pressure profiles in children and adolescents with classical congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Clin Endocrinol Metab 2006;91:4888–95.10.1210/jc.2006-1069Search in Google Scholar PubMed

46. Ubertini G, Bizzarri C, Grossi A, Gimigliano F, Rava L, et al. Blood Pressure and Left Ventricular Characteristics in Young Patients with Classical Congenital Adrenal Hyperplasia due to 21-Hydroxylase Deficiency. Int J Pediatr Endocrinol 2009;2009:383610.10.1186/1687-9856-2009-383610Search in Google Scholar

47. Hoepffner W, Herrmann A, Willgerodt H, Keller E. Blood pressure in patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Pediatr Endocrinol Metab 2006;19:705–11.10.1515/JPEM.2006.19.5.705Search in Google Scholar

48. Nebesio TD, Eugster EA. Observation of hypertension in children with 21-hydroxylase deficiency: a preliminary report. Endocrine 2006;30:279–82.10.1007/s12020-006-0005-4Search in Google Scholar PubMed

49. de Silva KS, Kanumakala S, Brown JJ, Jones CL, Warne GL. 24-hour ambulatory blood pressure profile in patients with congenital adrenal hyperplasia–a preliminary report.J Pediatr Endocrinol Metab 2004;17:1089–95.10.1515/JPEM.2004.17.8.1089Search in Google Scholar

50. Liivak K, Tillmann V. 24-hour blood pressure profiles in children with congenital adrenal hyperplasia on two different hydrocortisone treatment regimens. J Pediatr Endocrinol Metab 2009;22:511–7.10.1515/JPEM.2009.22.6.511Search in Google Scholar PubMed

51. Mallappa A, Sinaii N, Kumar P, Whitaker MJ, Daley LA, et al. A phase 2 study of Chronocort, a modified-release formulation of hydrocortisone, in the treatment of adults with classic congenital adrenal hyperplasia. J Clin Endocrinol Metab 2015;100:1137–45.10.1210/jc.2014-3809Search in Google Scholar PubMed PubMed Central

52. Reynolds RM, Walker BR. Human insulin resistance: the role of glucocorticoids. Diabetes Obes Metab 2003;5:5–12.10.1046/j.1463-1326.2003.00221.xSearch in Google Scholar PubMed

Received: 2017-2-12
Accepted: 2017-7-20
Published Online: 2017-8-8
Published in Print: 2017-8-28

©2017 Walter de Gruyter GmbH, Berlin/Boston

Articles in the same Issue

  1. Frontmatter
  2. Original Articles
  3. Standard body mass index reference data of prepubescent diabetic Egyptian children
  4. Frequency and risk factors of depression in type 1 diabetes in a developing country
  5. Association of obesity and health related quality of life in Iranian children and adolescents: the Weight Disorders Survey of the CASPIAN-IV study
  6. Association between urinary phthalates and metabolic abnormalities in obese Thai children and adolescents
  7. A pilot study of the effect of human breast milk on urinary metabolome analysis in infants
  8. Assessment of the correlation between the atherogenic index of plasma and cardiometabolic risk factors in children and adolescents: might it be superior to the TG/HDL-C ratio?
  9. Cardiovascular and metabolic risk in pediatric patients with congenital adrenal hyperplasia due to 21 hydroxylase deficiency
  10. Application of povidone-iodine at delivery significantly increases maternal urinary iodine but not neonatal thyrotropin in an area with iodine sufficiency
  11. Influence of topical iodine-containing antiseptics used during delivery on recall rate of congenital hypothyroidism screening program
  12. Applying targeted next generation sequencing to dried blood spot specimens from suspicious cases identified by tandem mass spectrometry-based newborn screening
  13. Short Communication
  14. Initial patient choice of a growth hormone device improves child and adolescent adherence to and therapeutic effects of growth hormone replacement therapy
  15. Case Reports
  16. An occult ectopic parathyroid adenoma in a pediatric patient: a case report and management algorithm
  17. Fetal goitrous hypothyroidism treated by intra-amniotic levothyroxine administration: case report and review of the literature
  18. Carotid intima media thickness in a girl with sitosterolemia carrying a homozygous mutation in the ABCG5 gene
  19. Sirolimus in the treatment of three infants with diffuse congenital hyperinsulinism
https://doi.org/10.1515/jpem-2017-0068
Keywords for this article
cardiovascular risk; congenital adrenal hyperplasia; hypertension; insulin resistance; obesity

Articles in the same Issue

  1. Frontmatter
  2. Original Articles
  3. Standard body mass index reference data of prepubescent diabetic Egyptian children
  4. Frequency and risk factors of depression in type 1 diabetes in a developing country
  5. Association of obesity and health related quality of life in Iranian children and adolescents: the Weight Disorders Survey of the CASPIAN-IV study
  6. Association between urinary phthalates and metabolic abnormalities in obese Thai children and adolescents
  7. A pilot study of the effect of human breast milk on urinary metabolome analysis in infants
  8. Assessment of the correlation between the atherogenic index of plasma and cardiometabolic risk factors in children and adolescents: might it be superior to the TG/HDL-C ratio?
  9. Cardiovascular and metabolic risk in pediatric patients with congenital adrenal hyperplasia due to 21 hydroxylase deficiency
  10. Application of povidone-iodine at delivery significantly increases maternal urinary iodine but not neonatal thyrotropin in an area with iodine sufficiency
  11. Influence of topical iodine-containing antiseptics used during delivery on recall rate of congenital hypothyroidism screening program
  12. Applying targeted next generation sequencing to dried blood spot specimens from suspicious cases identified by tandem mass spectrometry-based newborn screening
  13. Short Communication
  14. Initial patient choice of a growth hormone device improves child and adolescent adherence to and therapeutic effects of growth hormone replacement therapy
  15. Case Reports
  16. An occult ectopic parathyroid adenoma in a pediatric patient: a case report and management algorithm
  17. Fetal goitrous hypothyroidism treated by intra-amniotic levothyroxine administration: case report and review of the literature
  18. Carotid intima media thickness in a girl with sitosterolemia carrying a homozygous mutation in the ABCG5 gene
  19. Sirolimus in the treatment of three infants with diffuse congenital hyperinsulinism
Sign up now to receive a 20% welcome discount
Institutional Access
How does access work?
Have an idea on how to improve our website?
Please write us.
© 2025 De Gruyter Brill
Downloaded on 28.9.2025 from https://www.degruyterbrill.com/document/doi/10.1515/jpem-2017-0068/html
Scroll to top button